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bstract
Aim.  –  Studies in vitro have highlighted the potential involvement of neuregulin 1 (NRG1) in the regulation of energy metabolism. This effect has
lso been suggested in vivo, as intracerebroventricular injection of NRG1 reduces food intakes and weight gain in rodents. Thus, it was hypothesised
hat NRG1 might affect serum leptin levels in mice.
Methods.  –  Weight, food intakes, energy expenditure, spontaneous physical activity and serum leptin levels were evaluated in normal-weight
57BL/6JRJ mice following intraperitoneal administration of NRG1 (50 g/kg, three times/week) or saline for 8 weeks. Based on the results of
his first experiment, leptin-resistant obese db/db mice were then given NRG1 for 8 weeks.
Results.  –  Leptin serum concentrations were six times higher in C57BL/6JRJ mice treated with NRG1 than in the animals given saline. NRG1
reatment also reduced weight gain by 10% and food intakes by 15% compared with saline treatment, while energy expenditure remained unchanged.
n db/db mice, serum leptin concentrations, weight gain, food intakes, energy expenditure and spontaneous physical activity were not altered by
RG1 treatment.
Conclusion.  –  The decrease in food intakes and weight gain associated with NRG1 treatment in C57BL/6JRJ mice may be partly explained byncreased leptin levels, whereas db/db mice were not affected by the treatment, suggesting resistance to NRG1 in this pathological state.
 2014 Elsevier Masson SAS. All rights reserved.
eywords: NRG1; Obesity; Energy expenditure; Weight lossAbbreviations: NRG1, Neuregulin 1 ;ErbB, Erythroblastic leukaemia viral
ncogene homologue; RQ, Respiratory quotient; VHL, Vehicle (saline).
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262-3636/© 2014 Elsevier Masson SAS. All rights reserved..  Introduction
Neuregulin 1 (NRG1) belongs to the epidermal growth fac-
or family. Its biological activity is mediated by erythroblastic
eukaemia viral oncogene homologue (ErbB) receptors. NRG1
lays a fundamental role in both developing and mature heart tis-
ue, and NRG1 treatment has positive effects in cardiovascular
iseases [1]. Altered NRG1/ErbB signalling has been demon-
trated during the development and progression of many tumours
2]. Complex crosstalk between ErbB2 receptors and leptin
ppears to take place in cancer [3], and ErbB2 induces leptin
ranscriptional upregulation in human breast epithelial cells [4].
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s leptin plays a major role in energy balance regulation, and
iven the link between leptin and NRG1/ErbB signalling in can-
er, it was hypothesized that NRG1 treatment might alter leptin
evels.
Therefore, the effect of chronic (8-week) intraperitoneal (i.p.)
RG1 treatment on leptin, weight status, fat mass, food intakes,
hysical activity and energy expenditure was assessed in normal-
eight mice and, based on the results of this first experiment, in
eptin-resistant db/db mice also.
.  Methods
.1.  Animals
A total of 16 C57BL/6JRJ and 16 BKS(D)-Leprdb/JOrlRj
ice (10 weeks old), provided by CERJ Janvier (Le Genest-
aint-Isle, France), were kept in temperature-controlled
20–22 ◦C) cages (single-housed) with free access to water
nd food (A04 diet; Scientific Animal Food and Engineering,
rance). All animal husbandry and experimental procedures
ere in accordance with the current legislation on animal exper-
mentation, and were approved by the local ethics committee
CEMEA Auvergne, CE 97-12).
.2.  NRG1  treatment
Recombinant NRG1 (beta-2a; Zensun Sci and Tech,
hanghai, China) [5] at 50 g/kg body weight or an equiva-
ent volume of 0.9% NaCl (sodium chloride) was administered
y i.p. injection three times a week for 8 weeks (n  = 8 for each
roup). Mice were euthanised 3 days after the end of treatment.
.3.  Food  intakes,  body  mass  and  body  composition
Body weight and food intakes were recorded every week
uring the treatment period. One week before sacrifice, body
omposition was evaluated by quantitative nuclear magnetic res-
nance imaging (EchoMRI; Echo Medical Systems, Houston,
X, USA).
.4.  Daily  energy  expenditure  and  physical  activity
VO2, VCO2 and physical activity were measured in mice
sing a PhenoMaster/LabMaster home cage system (TSE
ystems, Bad Homburg, Germany). Energy expenditure was
alculated using the Weir equation [6] from measurements of
as exchanges computed for each cage from data sampled
very 5 min. Respiratory quotient (RQ) was determined from
CO2/VO2. Spontaneous activity was measured using three-
imensional meshes of light beams. For adaptation, mice were
laced in individual calorimetric cages (22 ◦C) for 24 h prior to
ata collection. Daily energy expenditure and physical activity
ere computed for a 24-h period.
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.5.  Leptin  measurement
Serum leptin was evaluated with an ELISA kit (Abcam,
ambridge, MA, USA), and samples were read at 450 nm using
 PowerWave spectrophotometer (US BioTek, North Shoreline,
A, USA).
.6.  Statistical  analysis
SPSS Advanced Statistics software was used for the statisti-
al analysis (IBM, Armonk, NY, USA). Data are presented as
he mean ±  SEM. One-way analysis of variance (ANOVA) with
epeated measures was performed to assess weight and food
ntake changes following NRG1 or saline treatment. Unpaired
tudent’s t  test was used where appropriate. Statistical signifi-
ance was set at P < 0.05.
.  Results
.1.  NRG1  increases  serum  leptin  and  decreases  weight
ain, food  intakes  and  spontaneous  physical  activity  in
57BL/6JRJ  mice
On evaluating NRG1 effects in C57BL/6JRJ mice (Fig. 1),
erum leptin was strongly increased compared with the
aline vehicle (VHL)-treated animals (183.4 ±  46.6 pg.mL−1 vs.
9.5 ±  5.1 pg.mL−1, respectively; P  < 0.05; Fig. 1A). The VHL
roup also gained 9.6% in body mass (from 25.1 ±  0.95 g to
7.6 ±  0.85 g) whereas, in NRG1-treated mice, weight remained
table (from 26.6 ±  0.52 g to 26.1 ±  0.43 g) with treatment
Fig. 1B). Similarly, food intakes increased by 15.3% in the VHL
roup (from 27.1 ±  0.59 g.week−1 to 31.5 ±  1.5 g.week−1;
 < 0.05; Fig. 1C), but did not change in NRG1-treated mice
from 29.3 ±  0.57 g.week−1 to 29.3 ±  0.69 g.wk−1; Fig. 1C).
t the end of the treatment period, body fat percentages were
ower in the NRG1 than in the VHL group (12.5 ±  0.67% vs.
6.3 ±  0.91%, respectively; P  < 0.05; Fig. 1D). Daily energy
xpenditure (Fig. 1E) and RQ (not shown) did not differ between
he groups. Spontaneous activity over 24 h and at night was
ower in the NRG1 than in the VHL group (288.2 ±  31.5 m vs.
02.6 ±  102.3 m and 227.7 ±  24.9 vs.  373.6 ±  56.1 m, respec-
ively; P < 0.05), whereas diurnal activity was similar in both
roups (Fig. 1F).
.2.  NRG1  has  no  effect  on  serum  leptin,  weight  gain,  food
ntakes  or  spontaneous  physical  activity  in  db/db  mice
As NRG1 treatment increased serum leptin levels in
57BL/6JRJ mice, it was postulated that NRG1 effects might be
lunted in leptin-resistant db/db mice. Serum leptin concentra-
ions were comparable in both NRG1- and VHL-treated db/db
ice (Fig. 2A). Similarly, weight (Fig. 2B) and food intakes
Fig. 2C) remained stable in both groups of db/db mice, and the
ercentage of body fat was also comparable in both groups at
he end of treatment (Fig. 2D). Energy expenditure (Fig. 2E),
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Fig. 1. Effects of 8-week neuregulin 1 (NRG1) and saline (VHL) intraperitoneal treatment in normal-weight C57BL/6JRJ mice. (A) Serum leptin concentrations at
the end of NRG1 (50 g.kg−1) and saline treatment; variations (as percentages) in (B) body weight and (C) food intake during NRG1 and saline treatment; and (D)
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ice.
Q (not shown) and spontaneous physical activity (Fig. 2F) did
ot significantly differ between groups.
.  Discussion
Our results show that, in C57BL/6JRJ mice, NRG1 treatment
ncreases serum leptin concentrations, prevents weight gain and
owers food intakes compared with saline-treated controls. In
ontrast, NRG1 had no significant effects in db/db mice.
The strong leptin increase in C57BL/JJRJ mice after 8 weeks
f NRG1 treatment might explain the decreases in food intakes,
eight gain and body fat percentages, as shown previously with
i
teatment. Values are means ± SEM (n = 8/condition). *P < 0.05 vs. VHL-treated
eptin treatment [7]. The cause of the leptin increase, however, is
nknown. Leptin production is indirectly under insulin control
ia the PI3 K/AKT signalling pathway [8], and NRG1 stimulates
his pathway in muscle cells [9]. ErbB2 activation upregulates
eptin in human breast epithelial cells [4]. However, it is not
nown whether NRG1 administration can affect white adipose
issue, the main leptin producer [8]. The fact that ErbB receptors
re expressed in human preadipocytes [10] allows the assump-
ion that adipose tissue may be involved in the NRG1-mediated
ncrease in leptin.
Alternatively, leptin levels might be regulated centrally, as
he brain has been shown to express leptin and to release it into
G. Ennequin et al. / Diabetes & Metabolism 41 (2015) 168–172 171
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mig. 2. Effects of 8-week intraperitoneal treatment with neuregulin 1 (NRG1) a
RG1 (50 g.kg−1) and saline treatment; variations (as percentages) in (B) bo
xpenditure and (F) spontaneous physical activity at the end of treatment. Value
he bloodstream [11]. Indeed, intracerebroventricular injection
f NRG1 in hamsters had effects on food intakes and weight
ain similar to those reported in our study [12], suggesting that
he brain may be participating in the NRG1-mediated increase
n circulating leptin, although it cannot be excluded that NRG1
ffects may also be independent of leptin. Also, there is evi-
ence to suggest that NRG1 could also have leptin-independent
ffects. Spontaneous physical activity was markedly decreased
n normal-weight mice, as previously reported [12], while total
nergy expenditure was not affected by NRG1 treatment.These results suggest that the resting metabolic rate, which
epresents a major component of total energy expenditure (about
6% in mice [13]), could compensate for the decreased energy
u
c
Mline (VHL) in obese db/db mice. (A) Serum leptin concentrations at the end of
ight and (C) food intake between weeks 1 and 8; and (D) body fat, (E) energy
means ± SEM (n = 8/condition).
xpenditure from physical activity, resulting in unchanged total
aily energy expenditure. Nevertheless, leptin is known to
ncrease both spontaneous physical activity and energy expen-
iture [14]. Therefore, our present results suggest a complex
ction of NRG1 whereby food intakes and weight gain are
oth decreased possibly through an increase in leptin, while
hysical activity and energy expenditure are limited through
nknown pathways. However, the possibility of a side-effect
nduced by NRG1 treatment that might promote a decrease in
ouse locomotion cannot be ruled out, although human studiessing comparable dose ranges have shown no such signifi-
ant side-effect induced by chronic NRG1 treatment [15,16].
ore studies are now needed to elucidate the origin of the
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RG1-induced increase in circulating leptin and the contribu-
ion of increased circulating leptin to altered food intakes and
eight gain.
Unexpectedly, none of the effects observed in C57BL/6JRJ
ice following NRG1 treatment were seen in the leptin-resistant
bese db/db mice, and serum leptin concentrations did not
ncrease. This result suggests that the NRG1/ErbB signalling
athway might be impaired in these mice. As NRG1 activates
he PI3K/Akt pathway [9], insulin resistance in db/db mice could
ave inhibited leptin production, which is triggered by these
inases [10]. Moreover, palmitate impairs NRG1 signalling in
at cardiac myocytes [17]. This suggests that the dyslipidaemia
ommonly seen in metabolic diseases, and particularly in db/db
ice, might perturb NRG1 signalling. Such an NRG1-resistant
tate could, in turn, result in silenced leptin upregulation.
In conclusion, our present study has demonstrated that
hronic NRG1 administration increases serum leptin concen-
ration in normal-weight mice, and this increase might partly
xplain the reduction in food intakes, body weight gain and
ody fat percentage in these mice. On the other hand, NGR1
reatment appeared to have no such effects in obese db/db mice,
uggesting ‘NRG1 resistance’ in this pathological state.
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